At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
UNCY Unicycive Therapeutics, Inc.
Post-Market Trading 04-29 18:34:46 EDT
1.22
+0.19
+18.45%
盘后1.25
+0.03+2.43%
18:25 EDT
High1.29Low1.01Vol1.99M
Open1.02D1 Closing1.03Amplitude27.09%
Mkt Cap42.40MTradable Cap16.76MTotal Shares34.76M
T/O2.36MT/O Rate14.48%Tradable Shares13.74M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler
TipRanks  ·  01:37
These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler
Buy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial Positioning
TIPRANKS  ·  04-12
Buy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial Positioning
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
StreetInsider  ·  04-10
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
Unicycive Therapeutics: A Strong Buy on OLC’s Potential to Revolutionize Hyperphosphatemia Treatment in CKD
TIPRANKS  ·  04-04
Unicycive Therapeutics: A Strong Buy on OLC’s Potential to Revolutionize Hyperphosphatemia Treatment in CKD
CORRECTION: On Friday, Unicycive Therapeutics Reported Q4 EPS Of $(0.22), Which Missed $(0.17) Estimate
Benzinga  ·  04-01
CORRECTION: On Friday, Unicycive Therapeutics Reported Q4 EPS Of $(0.22), Which Missed $(0.17) Estimate
Buy Rating Affirmed for Unicycive Therapeutics Amidst Positive Milestones and Solid Financial Footing
TIPRANKS  ·  04-01
Buy Rating Affirmed for Unicycive Therapeutics Amidst Positive Milestones and Solid Financial Footing
Unicycive Therapeutics GAAP EPS of -$1.28, revenue of $0.7M
seekingalpha  ·  03-29
Unicycive Therapeutics GAAP EPS of -$1.28, revenue of $0.7M
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire  ·  03-28
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  03-25
Calendar of U.S. Earnings Expected in the Week Ahead
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
GlobeNewswire  ·  03-25
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
BRIEF-Unicycive Therapeutics Inc Entered Into A Securities Purchase Agreement With Certain Accredited Investors
Reuters  ·  03-15
BRIEF-Unicycive Therapeutics Inc Entered Into A Securities Purchase Agreement With Certain Accredited Investors
Unicycive Shares Climb on $50 Million Private Placement
Dow Jones  ·  03-14
Unicycive Shares Climb on $50 Million Private Placement
MNMD, SMR and VERI are among pre market gainers
seekingalpha  ·  03-14
MNMD, SMR and VERI are among pre market gainers
Buy Rating on Unicycive Therapeutics Amidst Promising UNI-494 Drug Candidate Prospects
TIPRANKS  ·  03-14
Buy Rating on Unicycive Therapeutics Amidst Promising UNI-494 Drug Candidate Prospects
Unicycive Announces $50 Million Private Placement
GlobeNewswire  ·  03-14
Unicycive Announces $50 Million Private Placement
Noble Financial Keeps Their Buy Rating on Unicycive Therapeutics (UNCY)
TIPRANKS  ·  03-11
Noble Financial Keeps Their Buy Rating on Unicycive Therapeutics (UNCY)
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
GlobeNewswire  ·  03-07
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
Buy Rating Affirmed for Unicycive Therapeutics Amidst Promising UNI-494 Developments and FDA Orphan Drug Designation
TIPRANKS  ·  03-05
Buy Rating Affirmed for Unicycive Therapeutics Amidst Promising UNI-494 Developments and FDA Orphan Drug Designation
BUZZ-Unicycive Therapeutics rises on FDA's 'orphan' tag for kidney failure drug
Reuters  ·  03-04
BUZZ-Unicycive Therapeutics rises on FDA's 'orphan' tag for kidney failure drug

Introduction

Company Name.
Unicycive Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Issue price:
--